RHIZEN-PHARMACEUTICALS
2.12.2020 10:35:17 CET | Business Wire | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19 ”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Khazna Awarded Uptime Tier III Certification of Design Documents for Ajman, UAE Facility, Largest in Company’s Portfolio24.2.2026 10:00:00 CET | Press release
Set to Achieve 1st Certified AI Data Center with Liquid Cooling in Middle East Uptime Institute, the Global Digital Infrastructure Authority, today announced that Khazna Data Centers, a global leader in hyperscale digital infrastructure, has achieved the Uptime Institute Tier III Certification of Design Documents (TCDD) award for its newest 100 MW AI-optimized data center, QAJ01 —set to be the first certified AI data center with liquid cooling in the Middle East and North Africa region. Representing the largest facility in Khazna’s portfolio, this state-of-the-art development features 20 data halls, each delivering 5 MW of IT capacity, purpose-built to meet the demands of next-generation artificial intelligence (AI) workloads. The certification underscores Khazna’s commitment to designing world-class, resilient, and efficient data center infrastructure in alignment with the industry’s most rigorous global standards. Located in Ajman, United Arab Emirates, the new facility has been desi
Infobip and ESA Boost Asteroid Impact Alerts with Instant Voice Calls24.2.2026 10:00:00 CET | Press release
New partnership accelerates response times for critical planetary defense alerts Global cloud communications platform, Infobip, has partnered with the European Space Agency (ESA) to improve the delivery of asteroid impact alerts via Infobip's Voice API solutions. Using Infobip’s platform, ESA personnelnow receive instant voice calls, enabling faster, 24/7 alerts for potential asteroid impacts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224294384/en/ European Space Agency partners with Infobip for asteroid impact alerts. Understanding the trajectories of asteroids, particularly those approaching Earth, known as near-Earth objects (NEOs), is crucial and time sensitive. As single asteroid impact 65 million years ago wiped out most life on Earth, it is vital for the ESA to identify all hazardous asteroids to better understand their physical characteristics and the potential consequences of an impact. Previously, ESA perso
ElevenEs held 1st Closing of its Series B Investment Round Backed by Caterpillar Venture Capital Inc.24.2.2026 09:24:00 CET | Press release
Construction of its 1GWh LFP Battery Cell Mega Factory to Begin in February 2026. ElevenEs has completed the first closing of its Series B investment round, backed by Caterpillar Venture Capital Inc., a wholly owned subsidiary of Caterpillar Inc. (NYSE: CAT) - the world’s leading manufacturer of construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. Additionally, an affiliate of BST (HK) Ltd., a leading Hong Kong-based commodity trading house, participated in the round. This transaction represents a significant milestone in the future of European battery manufacturing as the proceeds will be used for the initial phases of infrastructure and equipment toward the planned 1GWh Mega-Factory, with construction starting in February 2026. The first battery cell deliveries are expected in 2027. This project positions ElevenEs at the forefront of the global energy transition and marks a significant step forward in
PUR Appoints Dr. Daniel Klier as Chief Executive Officer24.2.2026 09:00:00 CET | Press release
Seasoned sustainability and climate finance leader to guide PUR’s next phase of growth PUR (the “Company”), a pioneer in Nature-based Solutions, today announced the appointment of Dr. Daniel Klier as Chief Executive Officer, subject to regulatory approval. Founded nearly two decades ago, PUR partners with farming communities globally to deliver agroforestry, reforestation, and landscape restoration projects. The Company generates verified carbon reductions and carbon credits that help corporates reduce supply chain emissions through high-integrity insetting and climate contributions within and beyond their own value chains, while improving soil health, water resources, and long-term farm productivity. PUR is a recognized leader in resilient coffee and cocoa value chains, reforestation, mangrove restoration, and ecosystem conservation, delivering measurable benefits for ecosystems, agriculture, and farming communities. Dr. Klier’s appointment marks the next phase of PUR’s development as
BearingPoint launches new services to help organizations gain full software transparency and meet EU Cyber Resilience Act requirements ahead of the 2027 deadline24.2.2026 09:00:00 CET | Press release
BearingPoint’s new SBOM Management and CRA Compliance Services strengthen software supply chain security. BearingPoint announces the launch of two new service offerings designed to address the growing complexity of software supply chains and the upcoming regulatory requirements under the EU Cyber Resilience Act (CRA): SBOM Management Services and CRA Compliance Services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224192962/en/ BearingPoint announces the launch of two new service offerings designed to address the growing complexity of software supply chains and the upcoming regulatory requirements under the EU Cyber Resilience Act (CRA): SBOM Management Services and CRA Compliance Services. Modern software products often contain thousands of components, many of which are open source or sourced from third-party suppliers. As supply chain attacks become more frequent and regulations tighten, organizations need complete v
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom